Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 30, 2026.

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells

Franziska Baenke, Barbara Chaneton, Matthew Smith and 10 more (opens in a new tab)

Molecular Oncology · 2015 · CC BY

doi:10.1016/j.molonc.2015.08.003 (opens in a new tab)

Abstract

BRAF inhibitors can extend progression‐free and overall survival in melanoma patients whose tumors harbor mutations in BRAF. However, the majority of patients eventually develop resistance to these drugs. Here we show that BRAF mutant melanoma cells that have developed acquired resistance to BRAF inhibitors display increased oxidative metabolism and increased dependency on mitochondria for survival. Intriguingly, the increased oxidative metabolism is associated with a switch from glucose to glutamine metabolism and an increased dependence on glutamine over glucose for proliferation. We show that the resistant cells are more sensitive to mitochondrial poisons and to inhibitors of glutaminolysis, suggesting that targeting specific metabolic pathways may offer exciting therapeutic opportunities to treat resistant tumors, or to delay emergence of resistance in the first‐line setting.

References 46

  1. 1.

    Cantor, J.R., Sabatini, D.M., 2012 Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881–898.

    Not in our library10.1158/2159-8290.cd-12-0345 (opens in a new tab)

  2. 2.

    Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C., Maddocks, O.D., Chokkathukalam, A., Coyle, J.E., Jankevics, A., Holding, F.P., Vousden, K.H., Frezza, C., O'Reilly, M., Gottlieb, E., 2012 Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 491, 458–462.

    Not in our library10.1038/nature11540 (opens in a new tab)

  3. 3.
    Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor · 2013
    No notice
  4. 4.

    Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liau, L.M., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G., Su, S.M., 2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462, 739–744.

    Not in our library10.1038/nature08617 (opens in a new tab)

  5. 5.

    Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., Futreal, P.A., 2002 Mutations of the BRAF gene in human cancer. Nature. 417, 949–954.

    Not in our library10.1038/nature00766 (opens in a new tab)

  6. 6.

    Dhomen, N., Marais, R., 2009 BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529–545. ix

    Not in our library10.1016/j.hoc.2009.04.001 (opens in a new tab)

  7. 7.

    Frezza, C., Zheng, L., Folger, O., Rajagopalan, K.N., MacKenzie, E.D., Jerby, L., Micaroni, M., Chaneton, B., Adam, J., Hedley, A., Kalna, G., Tomlinson, I.P., Pollard, P.J., Watson, D.G., Deberardinis, R.J., Shlomi, T., Ruppin, E., Gottlieb, E., 2011 Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 477, 225–228.

    Not in our library10.1038/nature10363 (opens in a new tab)

  8. 8.

    Girotti, M.R., Saturno, G., Lorigan, P., Marais, R., 2014 Sep No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol. Oncol. 8, (6) 1140–1158.

    Not in our library10.1016/j.molonc.2014.07.027 (opens in a new tab)

  9. 9.

    Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., Lorigan, P., Springer, C., Larkin, J., Jorgensen, C., Marais, R., 2013 Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158–167.

    Not in our library10.1158/2159-8290.cd-12-0386 (opens in a new tab)

  10. 10.

    Gomes, L.C., Di Benedetto, G., Scorrano, L., 2011 Essential amino acids and glutamine regulate induction of mitochondrial elongation during autophagy. Cell Cycle. 10, 2635–2639.

    Not in our library10.4161/cc.10.16.17002 (opens in a new tab)

  11. 11.
    Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene · 2013
    No notice
  12. 12.

    Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G.C., Frederick, D.T., Hurley, A.D., Nellore, A., Kung, A.L., Wargo, J.A., Song, J.S., Fisher, D.E., Arany, Z., Widlund, H.R., 2013 Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 23, 302–315.

    Not in our library10.1016/j.ccr.2013.02.003 (opens in a new tab)

  13. 13.

    Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, W.H., Kaempgen, E., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A.M., Swann, S., Haney, P., Mirakhur, B., Guckert, M.E., Goodman, V., Chapman, P.B., 2012 Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380, 358–365.

    Not in our library10.1016/s0140-6736(12)60868-x (opens in a new tab)

  14. 14.
    Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF · 2010
    No notice
  15. 15.

    Johannessen, C.M., Boehm, J.S., Kim, S.Y., Thomas, S.R., Wardwell, L., Johnson, L.A., Emery, C.M., Stransky, N., Cogdill, A.P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R.R., Salehi-Ashtiani, K., Hill, D.E., Vidal, M., Zhao, J.J., Yang, X., Alkan, O., Kim, S., Harris, J.L., Wilson, C.J., Myer, V.E., Finan, P.M., Root, D.E., Roberts, T.M., Golub, T., Flaherty, K.T., Dummer, R., Weber, B.L., Sellers, W.R., Schlegel, R., Wargo, J.A., Hahn, W.C., Garraway, L.A., 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468, 968–972.

    Not in our library10.1038/nature09627 (opens in a new tab)

  16. 16.

    Johannessen, C.M., Johnson, L.A., Piccioni, F., Townes, A., Frederick, D.T., Donahue, M.K., Narayan, R., Flaherty, K.T., Wargo, J.A., Root, D.E., Garraway, L.A., 2013 A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 504, 138–142.

    Not in our library10.1038/nature12688 (opens in a new tab)

  17. 17.

    Komurov, K., Tseng, J.T., Muller, M., Seviour, E.G., Moss, T.J., Yang, L., Nagrath, D., Ram, P.T., 2012 The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol. Syst. Biol. 8, 596

    Not in our library10.1038/msb.2012.25 (opens in a new tab)

  18. 18.

    Le, A., Lane, A.N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C.J., Slusher, B.S., Zhang, H., Zimmerman, L.J., Liebler, D.C., Slebos, R.J., Lorkiewicz, P.K., Higashi, R.M., Fan, T.W., Dang, C.V., 2012 Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110–121.

    Not in our library10.1016/j.cmet.2011.12.009 (opens in a new tab)

  19. 19.

    Lito, P., Rosen, N., Solit, D.B., 2013 Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401–1409.

    Not in our library10.1038/nm.3392 (opens in a new tab)

  20. 20.

    Maertens, O., Johnson, B., Hollstein, P., Frederick, D.T., Cooper, Z.A., Messaien, L., Bronson, R.T., McMahon, M., Granter, S., Flaherty, K.T., Wargo, J.A., Marais, R., Cichowski, K., 2013 Mar Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, (3) 338–349.

    Not in our library10.1158/2159-8290.cd-12-0313 (opens in a new tab)

  21. 21.
    PGC-1α supports glutamine metabolism in breast cancer · 2013
    No notice
  22. 22.

    Menzies, A.M., Long, G.V., 2013 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther. Adv. Med. Oncol. 5, 278–285.

    Not in our library10.1177/1758834013499637 (opens in a new tab)

  23. 23.

    Metallo, C.M., Gameiro, P.A., Bell, E.L., Mattaini, K.R., Yang, J., Hiller, K., Jewell, C.M., Johnson, Z.R., Irvine, D.J., Guarente, L., Kelleher, J.K., Vander Heiden, M.G., Iliopoulos, O., Stephanopoulos, G., 2012 Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 481, 380–384.

    Not in our library10.1038/nature10602 (opens in a new tab)

  24. 24.

    Montagut, C., Sharma, S.V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L.E., Dias-Santagata, D., Stubbs, H., Lee, D.Y., Singh, A., Drew, L., Haber, D.A., Settleman, J., 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853–4861.

    Not in our library10.1158/0008-5472.can-07-6787 (opens in a new tab)

  25. 25.

    Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.K., Attar, N., Sazegar, H., Chodon, T., Nelson, S.F., McArthur, G., Sosman, J.A., Ribas, A., Lo, R.S., 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468, 973–977.

    Not in our library10.1038/nature09626 (opens in a new tab)

  26. 26.

    Parmenter, T.J., Kleinschmidt, M., Kinross, K.M., Bond, S.T., Li, J., Kaadige, M.R., Rao, A., Sheppard, K.E., Hugo, W., Pupo, G.M., Pearson, R.B., McGee, S.L., Long, G.V., Scolyer, R.A., Rizos, H., Lo, R.S., Cullinane, C., Ayer, D.E., Ribas, A., Johnstone, R.W., Hicks, R.J., McArthur, G.A., 2014 Apr Response of BRAF mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 4, (4) 423–433.

    Not in our library10.1158/2159-8290.cd-13-0440 (opens in a new tab)

  27. 27.

    Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M.T., Salton, M., Dahlman, K.B., Tadi, M., Wargo, J.A., Flaherty, K.T., Kelley, M.C., Misteli, T., Chapman, P.B., Sosman, J.A., Graeber, T.G., Ribas, A., Lo, R.S., Rosen, N., Solit, D.B., 2011 RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480, 387–390.

    Not in our library10.1038/nature10662 (opens in a new tab)

  28. 28.

    Puigserver, P., Spiegelman, B.M., 2003 Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24, 78–90.

    Not in our library10.1210/er.2002-0012 (opens in a new tab)

  29. 29.

    Sanchez-Laorden, B., Viros, A., Girotti, M.R., Pedersen, M., Saturno, G., Zambon, A., Niculescu-Duvaz, D., Turajlic, S., Hayes, A., Gore, M., Larkin, J., Lorigan, P., Cook, M., Springer, C., Marais, R., 2014 BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 7, ra30

    Not in our library10.1126/scisignal.2004815 (opens in a new tab)

  30. 30.

    Scott, D.A., Richardson, A.D., Filipp, F.V., Knutzen, C.A., Chiang, G.G., Ronai, Z.A., Osterman, A.L., Smith, J.W., 2011 Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 286, 42626–42634.

    Not in our library10.1074/jbc.m111.282046 (opens in a new tab)

  31. 31.

    Shi, H., Kong, X., Ribas, A., Lo, R.S., 2011 Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71, 5067–5074.

    Not in our library10.1158/0008-5472.can-11-0140 (opens in a new tab)

  32. 32.

    Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I., Golub, T.R., Sebolt-Leopold, J., Sellers, W.R., Rosen, N., 2006 BRAF mutation predicts sensitivity to MEK inhibition. Nature. 439, 358–362.

    Not in our library10.1038/nature04304 (opens in a new tab)

  33. 33.

    Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K.D., Amaravadi, R.K., Chmielowski, B., Lawrence, H.J., Shyr, Y., Ye, F., Li, J., Nolop, K.B., Lee, R.J., Joe, A.K., Ribas, A., 2012 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714.

    Not in our library10.1056/nejmoa1112302 (opens in a new tab)

  34. 34.

    Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., Cooper, Z.A., Chapman, P.B., Solit, D.B., Ribas, A., Lo, R.S., Flaherty, K.T., Ogino, S., Wargo, J.A., Golub, T.R., 2012 Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487, 500–504.

    Not in our library10.1038/nature11183 (opens in a new tab)

  35. 35.

    Vander Heiden, M.G., Lunt, S.Y., Dayton, T.L., Fiske, B.P., Israelsen, W.J., Mattaini, K.R., Vokes, N.I., Stephanopoulos, G., Cantley, L.C., Metallo, C.M., Locasale, J.W., 2011 Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 76, 325–334.

    Not in our library10.1101/sqb.2012.76.010900 (opens in a new tab)

  36. 36.

    Vazquez, F., Lim, J.H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C.B., Granter, S.R., Widlund, H.R., Spiegelman, B.M., Puigserver, P., 2013 PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 23, 287–301.

    Not in our library10.1016/j.ccr.2012.11.020 (opens in a new tab)

  37. 37.

    Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., Marais, R., 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116, 855–867.

    Not in our library10.1016/s0092-8674(04)00215-6 (opens in a new tab)

  38. 38.

    Wang, Q., Beaumont, K.A., Otte, N.J., Font, J., Bailey, C.G., van Geldermalsen, M., Sharp, D.M., Tiffen, J.C., Ryan, R.M., Jormakka, M., Haass, N.K., Rasko, J.E., Holst, J., 2014 Sep 1 Targeting glutamine transport to suppress melanoma cell growth. Int. J. Cancer. 135, (5) 1060–1071.

    Not in our library10.1002/ijc.28749 (opens in a new tab)

  39. 39.

    Ward, P.S., Thompson, C.B., 2012 Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 21, 297–308.

    Not in our library10.1016/j.ccr.2012.02.014 (opens in a new tab)

  40. 40.

    Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D.P., Koeppen, H., Merchant, M., Neve, R., Settleman, J., 2012 Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487, 505–509.

    Not in our library10.1038/nature11249 (opens in a new tab)

  41. 41.

    Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer, H.K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S.B., Thompson, C.B., 2008 Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A. 105, 18782–18787.

    Not in our library10.1073/pnas.0810199105 (opens in a new tab)

  42. 42.

    Xiang, Y., Stine, Z.E., Xia, J., Lu, Y., O'Connor, R.S., Altman, B.J., Hsieh, A.L., Gouw, A.M., Thomas, A.G., Gao, P., Sun, L., Song, L., Yan, B., Slusher, B.S., Zhuo, J., Ooi, L.L., Lee, C.G., Mancuso, A., McCallion, A.S., Le, A., Milone, M.C., Rayport, S., Felsher, D.W., Dang, C.V., 2015 Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293–2306.

    Not in our library10.1172/jci75836 (opens in a new tab)

  43. 43.
    Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer · 2014
    No notice
  44. 44.

    Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., Yan, H., Wang, W., Chen, S., Viale, A., Zheng, H., Paik, J.H., Lim, C., Guimaraes, A.R., Martin, E.S., Chang, J., Hezel, A.F., Perry, S.R., Hu, J., Gan, B., Xiao, Y., Asara, J.M., Weissleder, R., Wang, Y.A., Chin, L., Cantley, L.C., DePinho, R.A., 2012 Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 149, 656–670.

    Not in our library10.1016/j.cell.2012.01.058 (opens in a new tab)

  45. 45.

    Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J.H., Shen, C.H., Bosenberg, M.W., McMahon, M., Cantley, L.C., Zheng, B., 2013 Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc. Natl. Acad. Sci. U.S.A. 110, 18226–18231.

    Not in our library10.1073/pnas.1317577110 (opens in a new tab)

  46. 46.

    Zhao, Y., Liu, H., Liu, Z., Ding, Y., Ledoux, S.P., Wilson, G.L., Voellmy, R., Lin, Y., Lin, W., Nahta, R., Liu, B., Fodstad, O., Chen, J., Wu, Y., Price, J.E., Tan, M., 2011 Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 71, 4585–4597.

    Not in our library10.1158/0008-5472.can-11-0127 (opens in a new tab)

Cited by papers we hold 8

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.